The “Overnight Millionaires” of MIRACLE ISLAND

This small, fractured nation has quietly become a global mega-player in the $234 billion bio-pharma industry…

Here’s how YOU can join the new wave of Americans who are cashing in — if you move fast!

Dear American Profit Seeker,

The next big thing in extreme investing profits isn’t an invention, company, resource, or commodity…

In fact, it’s not a “thing” at all. It’s a place.

A small island nation, about the size of South Carolina.

At first glance, it seems a very unlikely location for investment returns of up to 10,000% — or more.

It’s a land with too much cold sea, raw wind, and hard rock…

And not enough infrastructure, heavy industry, or valuable natural resources.

As a whole, its people are among the poorest in the developed world.

For many of these islanders, the abundant food and energy we Americans take for granted are far from guaranteed.

In fact, 20% of them still warm their homes the way their tribal ancestors did…

With fireplaces full of decaying swamp grass!

Others burn filthy, toxic lumps of low-grade bituminous coal — if they can get it.

Another reason for this island’s widespread poverty and debt…

It’s been continuously plagued by war, famine, disease, invasion, civil unrest and religious strife for more than 1,000 years.

Look, I could go on and on about this tragic place. But I’m sure you get my point….

By and large, it’s been a broken, bloody mess for most of recorded history.

But all that’s about to change — and those who play it MY way could end up richer than rich

Due to a historic convergence of factors I’m about to show you…

This small island nation is in the midst of becoming a global superpower.

Not politically or militarily…

But as an alpha player in one of the most explosively lucrative industries on Earth: Biotech.

I know this all sounds hard to believe…

But as I’m about to prove to you, it’s absolutely true.

In fact, their transformation from poverty-stricken welfare state to global economic heavyweight has already begun.

Even as you read these words, in fact…

Millions of doses of miraculous new treatments are rolling out of state-of-the-art production and distribution centers that have sprung up all over this island.

I’m talking about cutting-edge, biologically derived therapeutics for things like:

report HIV
report Neurological disorders
report Autoimmune diseases
report Diabetes
report Hepatitis
report Organ rejection
report Inflammation
report Nervous system disorders
report Schizophrenia
report Depression
report Thyroid disease
report Osteoporosis
report Bowel and digestive diseases
report Hormonal imbalances
report Many forms of cancer
report And much, much, more…

That’s why I call this place “Miracle Island”.

If it’s a drug that’s currently making waves in 21st-century medicine…

Odds are good that it’s being (or has been) developed, tested, produced, or distributed from this small island.

Take the miraculous medication that changed Elissa Levy’s life, for instance. You may actually have seen her story on the Today show…

Elissa was stricken with Multiple Sclerosis in the prime of life, just 33 years of age.

Over time, her condition declined until she could only walk short distances — and only with the aid of a cane.

And sometimes, a wheelchair was her only option for getting around…

But Elissa’s doctors weren’t giving up. They arranged for her to try an experimental drug called 4-Aminopyridine.

The results were nothing short of miraculous.

After barely being able to move her right leg for three years…

Elissa could actually get up out of her wheelchair and walk again — at normal speed.

And without a cane, even!

Then there’s Joe “Excalibur” Ellenberger, a world-ranked Mixed Martial Arts (MMA) fighter from Omaha, Nebraska…

Several years ago, in the midst of training for a big bout, Joe was diagnosed with an extremely rare form of genetically acquired anemia.

Called PNH, it’s a condition that’s fatal within five years in a third of patients diagnosed with it…

And debilitating in every case.

But today, thanks to an incredibly effective new drug called Eculizumab

Joe’s back in the cage, and swinging harder than ever.

In fact, he’s won five out of six fights since he began treatment with this new, biologically derived miracle drug.

And then there’s Liam, age 11, from New York…

He suffers from PKU, a rare genetic disease that affects the body’s ability to process necessary dietary proteins.

Without strict adherence to an ultra-limited, virtually zero-protein diet regimen…

PKU can lead to seizures and other serious medical problems, including severe mental impairment.

But just like Joe and Elissa, a miraculous new drug (called Sapropterin) — has changed Liam’s life radically…

Now he can even occasionally eat his favorite protein-rich foods: like fava beans!

I could tell you dozens more stories about the incredible drugs being made by the pioneering biotechs of Miracle Island…

But my goal with this bulletin isn’t to spread the word about life-changing cures.

It’s to help you make life-changing money on Miracle Island’s rise to global biotech supremacy.

As I’ll show you shortly, it isn’t just dumb luck driving this transformation…

There are bona-fide reasons why the world’s leading biotechs are flocking to this unlikely place — and springing up there left and right.

But the point I want to make sure you understand NOW is this…

Very few investors (or analysts) are looking at “Miracle Island” as a source of biotech gains in the 5,000% – 10,000% range

Most of them are still focused on the big American biotech companies — firms like Amgen, Biogen, Regeneron, Celgene, etc.

After all, the United States is the world’s undisputed biotech epicenter, with over 1,300 firms and counting…

But therein lies the problem.

Because the U.S. is the acknowledged global leader in biotechnology…

Literally millions of investors are watching every single American biotech like a hawk — around the clock.

So every development, clinical trial, partnership, inside stock purchase, merger, or mere rumor can send prices soaring instantly.

On the other hand…

Many of the biotechs based on “Miracle Island” aren’t household names to millions of U.S. investors yet.

So they’re not constantly spiking up on a bunch of news cycle hype.

Also, a lot of these firms are relatively young. They aren’t part of the “old guard”, like so many mature U.S. biotech companies…

So they haven’t yet experienced their biggest growth — not by a long shot.

These are just some of the reasons why Miracle Island is such a juicy profit opportunity. I’ll show you more in a moment.

But more important than that…

I’m also going to offer you three specific investments you can make right now to cash in on this emerging “overnight millionaire” opportunity.

Again, I’m talking about the strong potential for short-term returns of well up into the triple-digits

And at least the possibility for longer-term gains of up to 10,000% or more.

There is one small catch, though…

If you want to cash in BIG, you can’t drag your feet

I wouldn’t say the cat’s out of the bag on Miracle Island just yet, but it will be soon.

Very soon.

That’s because investors aren’t stupid…

And the truth is, juicy profits are already rolling in for biotech investors who’ve taken early positions in the right Miracle Island plays.

In fact, the number of millionaires on this historically dirt-poor island has practically tripled in just the last 2½ years — to over 90,000 today.

There are now even a few billionaires who call the place home.

So yeah, the word is getting out on this deal…

And that’s exactly why I’m speaking to you today.

Because I want to make sure you’re one of the new wave of “overnight millionaires” who’ll soon be living the high life (and living longer, to boot)…

Thanks to the emerging spoils of Miracle Island.

But again — and I can’t stress this enough: if you want to get in on the BIG money…

You must move decisively on what I’m about to show you.

However, before I just up and GIVE you the three specific plays you must make right now on Miracle Island’s “stealth” biotech boom…

And before I reveal exactly where this island is (you’ll be shocked)…

I want to formally introduce myself.

My name’s Nicholas Vardy.

I’m a Chartered Financial Analyst (CFA) — educated at Stanford and Harvard.

In fact, I’m one of the few analysts in financial publishing today who actually holds both a CFA and a Harvard law degree.

I’m also the international investment analyst for Eagle Financial Publications in Washington, DC.

That means it’s literally my job to report on the stories, scenarios, and opportunities that can make American investors money…

No matter where they originate in this world.

Don’t misunderstand — I’m red-white-and-blue, all the way through…

I hail from Pittsburgh, the son of Hungarian teachers who fled the Communist yoke to become U.S. citizens in the 1950s.

They risked their lives for the American dream, and to give that dream to me. That’s a debt I take seriously.

That’s why I’ve made it my mission in life to bring the richest fruits of that dream to earnest, hard-working American investors like you…

Through my Eagle Financial investment research advisories.

However, I can’t bring home the bacon for you if I don’t know where it’s cooking.

That’s why I now live in London, the center of the financial universe…

Where the very best investing intelligence on Earth comes from.

And every day, I use my one-of-a-kind network of contacts to gather and analyze that “intel” on behalf on my readers.

Seriously — I’ve got all the best international hedge fund honchos in my cell phone.

In fact, we regularly hang out at my place to compare notes on where the BIG money’s going to come from in the near future…

And of course, to drink beer, play poker, and talk about women (like my hot “Bond Girl” wife — and her two PhDs).

What does all this mean to you?

It means that from Tulsa to Tijuana to Timbuktu — if it’s an emerging situation you can profit from, I’ll give you a way to play it…

From the safety and familiarity of AMERICAN exchanges and investments.

In other words, the moneymaking tools you already know and trust.

In fact, I’ll bet you’ve seen me talking about how to do exactly that on World Business Tonight, MoneyShow.com, Fox Business, CNN International, and other financial programs…

No doubt you’ve also read my regular economics and investing commentary in MarketWatch, Newsweek, The Wall Street Journal, my own Global Guru, and more.

But really, whether you know me or not is sort of beside the point on this one.

Because with the evidence and facts I’m about to show you…

An untrained chimp could convince you to drop everything and bet the farm on the Miracle Island plays I’m about to hand you on a silver platter.

That’s not an overstatement, either.

I can honestly say that this emerging situation has the potential to be the biggest and fastest profit opportunity I’ve ever brought to my readers.

And that’s really saying something…

Because over the last few years, I’ve led readers of my Eagle Financial investment advisories to literally hundreds of lucrative scores.

These include over 100 triple-digit wins of up to 528%!

Mind you, most of these big scores came in the relatively short term…

From just a few months to a couple of years.

But here’s the thing: as impressive as fast, hefty wins like these may be to you…

Even my BIGGEST wins pale in comparison to what you could bank in biotech — if you know what you’re doing

Just to give you some food for thought…

80% of the best-performing IPOs of 2014 were biotech companies.

And the top 10 of these averaged year-over-year gains of more than 321%!

In other words, if you had parked some cash in the typical top-tier biotech at the beginning of last year…

You’d have more than quadrupled your money in 12 months.

And I don’t need to tell you how incredibly profitable the right biotech plays can be over the longer term.

Surely you’ve heard of gene-sequencing pioneer Illumina, and their 3,600% profit ride over the last decade…

No doubt Medivation, Inc. is on your radar, too. They’ve posted eye-popping 10-year returns of over 5,700%!

And let’s not forget Questcor Pharmceuticals’ run of over 24,000% from 2007 to 2014 (when they were bought out).

These kinds of returns are only possible in biotech right now.

Not commodities. Not banking. Not even healthcare. And certainly not energy.

However, there’s a HUGE catch to all this…

You can’t just pick a biotech at random, plunk your nest egg into it, and retire rich in ten years.

In fact, doing that would almost guarantee disaster.

Why?

Because the brutal truth is — depending on which biotech sector you’re playing (and there are several, as I’ll show you)…

As many as 9 out of 10 biotechnology companies fail.

So if you’re picking them with a dartboard, you’re going to lose your shirt.

However, with the right guidance (mine, in other words)…

There are TWO major things you can do to hedge your biotech bets — and turn the odds of banking a 10,000% biotech win solidly in your favor.

And yes, my three hot Miracle Island plays are going to help you do both of them.

The first is this…

Take square aim at biotech’s most lucrative sector

The vast “biotech” universe includes everything from stem cell research to gene sequencing to biofuels, GMO foods, and more…

And yes, there have been HUGE market winners in all of these sectors.

But these days, one particular segment of “biotech” is by far the fastest growing and most potentially lucrative for investors

Biopharmaceuticals.

Now, these can also be called “biologics”, “large-molecule drugs”, and other names.

But they all refer to the same thing…

Drugs that are extracted from biological sources — instead of synthesized through chemical processes (like conventional drugs).

I’m telling you: biopharma is where it’s at right now.

There are some absolute fortunes being made in this sector by a few connected, lucky, or exceptionally knowledgeable investors…

In fact, remember those “top 10 biotechs of 2014” I mentioned a minute ago?

You know, the ones that averaged 321% gains last year alone?

Well, nine out of 10 of them were biopharmaceutical companies…

In 2013, eight of the top 10 biotechs were biopharmas.

And after extensive analysis in this sector, I can assure you it’s only going to get hotter from here…

Let me prove that to you with just a few of the more stunning statistics:

report In 2014, the global biopharma industry was worth approximately $234 billion per year — a 17% year-over-year increase against 2013
report Projections show the industry topping $387 billion a year by 2019, a growth rate of more than 65% over the next four years
report There are already nearly 200 bio-pharmaceuticals in use worldwide — with 400 more currently in the pipeline (that’s an increase of over 200%)
report By 2030, up to 80% of the world’s pharmaceuticals and diagnostic medicine will be biologically based…
report Yet so far, only around 9% of the world’s people have used biologic drugs!

Incredible, isn’t it?

These last two bullet points are especially telling, and bear further analysis…

By 2030, 80% of the world’s drugs will be biopharmaceuticals — yet today, less than 10% of people have ever used them!

That’s a projected increase of more than 888%.

Can you think of ANY other industry with a realistic chance of multiplying nearly nine-fold in the next 15 years?

And I could go on and on with biopharma statistics just like these.

But again I remind you — my objective with this bulletin isn’t to catalog the scope and impact of the biopharmaceuticals industry…

It’s to GIVE you a trio of “Miracle Island” biopharma plays that I predict are going to be right in the thick of the juiciest profits.

And that brings me to the second thing I’m going to help you do to “hedge your bets” on the risky biotech sector…

Target the world’s hottest emerging biopharma clusters

More than any other industry I can think of…

Biopharmaceutical companies tend to “cluster up” in certain regions.

And with more than a dozen major technology clusters, the U.S. is the undisputed 800-lb gorilla of the biopharma space right now.

The “big three” of these are:

report California, specifically San Francisco, San Diego, and Los Angeles
report Massachusetts, especially around the Cambridge and Boston areas
report Maryland, particularly Montgomery County and other D.C. suburbs

There are also significant biopharma clusters in New York, New Jersey, Chicago, Seattle, Philadelphia, the Raleigh/Durham area of North Carolina…

And a few other places around the country.

Why do biopharma innovators tend to stack up in these specific areas?

There are a number of reasons.

Of course, some of them have to do with things like taxes, regulation, business climate, proximity to other forms of technology, etc.

But there’s one key factor that’s by far the most important…

An exceptionally educated work force.

In close proximity to every one of America’s major biopharma clusters…

You’ll find venerable institutions of higher learning — with strong programs in biology and technology.

Schools like Harvard, MIT, Johns Hopkins, The University of Maryland, Drexel, the University of California, Duke, UNC, North Carolina State, and many others…

In fact, you will NOT find a concentration of successful biotech companies anywhere without a pool of highly educated workers close at hand.

But as you know, the U.S. isn’t the only country with cutting-edge higher education.

In fact, there are many places around the world that now have science and tech education programs to rival anything found in the U.S….

A lot of them also have some of the other advantages I mentioned that have made America the world’s biotech leader thus far.

Consequently, there’s a whole new generation of up-and-coming biopharma hotbeds outside the United States.

Places like Shanghai, Tokyo, Stockholm, Helsinki, Toronto, New Delhi, Rio and Sao Paolo, Sydney, Brisbane, and Melbourne — and Cape Town, South Africa…

Even Cuba is quickly becoming a viable biotech player!

Now mark my words…

These emerging hotbeds are where the biggest money in biopharma is going to be made over the next 10 years.

Investors who get in early on the right companies in emerging biopharma hotbeds are going to score HUGE profits.

In fact, I’ll go on record predicting that the next 10,000% winner in this sector will come rocketing out of one of these places…

If not the next dozen of them!

And in my informed, completely objective opinion…

“Miracle Island” — AKA Ireland — is the very best of these emerging biopharma hotbeds

In case you haven’t guessed, I’ve been talking about none other than the Emerald Isle itself: Ireland.

Now again, I’m sure it must seem unlikely to you that this small, conflicted country…

A nation with some of the highest rates of poverty, alcoholism, and consumer debt in the developed world…

Could be the hottest emerging biotech powerhouse on the planet.

But it’s the absolute truth.

Believe it or not, Ireland has been a major player in conventional pharmaceuticals since the 1960s…

In fact, they’re the largest net exporter of medications in the world.

Nine of the top ten “Big Pharma” companies have major operations in Ireland…

And five of the world’s top 12 conventional drugs are manufactured there, among them Lipitor and Plavix.

But here’s the thing…

It’s NOT in conventional pharmaceuticals where Ireland is going to make its biggest mark on 21st century medicine.

It’s in biopharmaceuticals.

In fact, Ireland was billed as “The gateway to biopharma’s future” by industry media in November of 2014.

And for good reasons…

You see, as far back as the late 90s, the Irish government anticipated today’s massive shift to biopharmaceuticals.

And they began a concentrated effort to transform Ireland into a major global biopharma player.

They allocated $2.5 billion for technological development and education — an enormous sum for Ireland at the time.

They also launched their pioneering Programme for Research in Third Level Institutions

Which so far, has pumped nearly a billion dollars into promoting higher-quality research capabilities and facilities for Irish higher education.

They’ve invested another $80 million into a state-of-the-art training and research center specifically for biotechnology.

It’s called the National Institute for Bioprocessing Research and Testing (NIBRT)…

And it’s dedicated specifically to training Ireland’s workforce for success in all levels of the biotechnology industry.

It’s working, too — spectacularly.

In fact, immediately after opening its doors in 2011…

The NIBRT won the prestigious 2012 BioProcess International “Manufacturing Collaboration of the Decade” award.

And speaking of the Irish workforce…

It might surprise you to learn that they’re the best educated in all of Europe — bar none.

The Irish are a smart, studious, and tenacious people…

And the value of education is ingrained upon them from a very early age.

Plus, their education is almost entirely subsidized by the government…

Consequently, they’ve got more university, college, and tech school graduates per capita than any other country in the EU.

Ireland also has one of the youngest work forces in the world — with an average age of just 35!

This is a prime statistic for companies looking to get skilled, educated labor without having to pay the higher salaries of older employees…

Or deal with the looming pension burdens of a large number of employees nearing retirement age.

Now, as if all this weren’t enough reason for Ireland to become the next global biotech super-cluster…

Consider the Emerald Isle’s second-to-none business climate.

Recently voted #1 in Forbes’ “Best Countries for Business” list, Ireland also scored highly in 2014’s IMD World Competitiveness Yearbook.

This included being ranked the top nation in the world for such key categories as:

report Availability of skilled labor
report Workforce flexibility and adaptability
report Attitudes toward globalization
report Business investment incentives

Yet another feather in Ireland’s cap…

A recent survey of 4,300 executives ranked Ireland third highest out of 60 developed economies in perceived quality of business climate.

This was 21 places HIGHER than the U.S. — which ranked 24th!

Toss in low, 12.5% corporate tax rates and a 25% tax credit for in-house R&D…

And it’s no wonder biopharma superstars like BioMarin, Jazz, Alkermes, Alexion, and many others now base their international operations in Ireland.

In fact, more than 30 cutting-edge pharmas are either headquartered in Ireland, or have major international hubs there.

Ok, so now that you’ve got all the facts in front of you…

Isn’t it easy to see why I think Ireland is going to be the driving force behind the next 10,000% biopharma score?

Or like I said earlier, the next dozen of them?

If you’re not as convinced as I am by now, you never will be.

However, if you are convinced — and you’re ready to cash in

I want to GIVE you my three most urgent and potentially lucrative “Miracle Island” profit plays right now.

But again, these plays are very urgent, and you must move quickly on them.

Ready?

Here they are, no strings attached…

RIGHT NOW: The best chance of your life to become an “overnight millionaire”

Remember, my mission is to help you cash in on the world’s most lucrative situations — wherever they’re emerging…

Like the incredible biotech revolution that’s unfolding right now IN Ireland.

However, before I take you any farther down that road…

I just want to be perfectly clear about something right up front.

While it’s absolutely true that I’ve led my readers to over a hundred triple-digit wins of up to 528%

With most of them coming in well under a year

I can’t promise you a constant string of triple-digit wins if you become one of these readers (more on that in a moment).

No analyst or advisor in the world could do that — especially in biotech.

The truth is, I’ve never promised my readers ANY of the wins I’ve led them to…

What I promised was to use my unique position, education, and skill set to give them the very best investment recommendations I could.

And in more than 100 cases over the last seven years…

That was good enough to deliver triple-digit profits to readers of my Eagle Financial research services — sometimes in mere weeks.

It was also good enough to score them hundreds more solid, double-digit wins.

Here’s my point: I never overpromise and under-deliver to my readers…

In fact, I always strive to do just the opposite.

So no — I’m not guaranteeing to bank you 24,000% on the world’s next Questcor.

However, what I AM guaranteeing you is this…

As a world-renowned expert at helping American investors tap into extraordinary offshore profit opportunities…

No one is better able to put you into the huge biotech profits that are going to come out of “Miracle Island” than ME.

Bottom line: more than any other place on Earth right now…

And more than any other time in the recent past…

Ireland’s red-hot biopharma sector offers in-the-know investors the best possible chance of literally becoming an “overnight millionaire”.

Now again, I’m not promising you that.

But in my opinion, the three plays I’m about to offer you have a better chance of paying you the biggest gains

While exposing you to the lowest risks, relative to the sector at large…

Than any other biotech investments you can make right now.

So without further ado, here they are:

AN ULTRA-LOW-RISK BIOTECH THAT COULD STILL MAKE YOU RICH

Remember earlier, when I was telling you about how as many as 90% of biotech companies fail?

Well, this play is the ultimate “safe bet” within this high-risk sector. But don’t let that fool you…

There’s still stunning upside potential here, as my all-new biotech-focused Special Investment Report will show you.

It’s called My Safest Bet on Booming Biotech.

In it, you’ll find all the lucrative details on a juicy “Miracle Island” play that’s truly one of a kind…

What makes it so unique — and so low-risk?

Quite simply, the fact that it’s literally TWO pharma plays in one investment.

What I mean is that this company is already a major player in one of lowest-risk, yet most lucrative segments of the pharmaceuticals industry…

Generic drugs.

You just wouldn’t believe how far this Irish company’s reach extends in the $300 billion-a-year generics sector…

In fact, their presence will be felt in the drug markets of over 100 countries this year.

This is partly due to their aggressive expansion.

In the last four years alone, this company has sucked up over $36 billion worth of pharma industry assets.

But again — their prominence in conventional pharmaceuticals is only part of the profit story here…

In fact, I look at it as simply the stable foundation of a HUGE profit opportunity in the very near future.

I’m talking about the potentially enormous “biosimilar” drug market.

“Biosimilars” are just what they sound like: biopharmaceutical compounds that are very similar in composition to name-brand biologic drugs…

But much less expensive.

The global market for these “rip off” biopharmaceuticals is positively exploding.

In fact, this industry is predicted to expand nearly 20-fold by 2019!

The best part: the Irish company you’ll discover in My Safest Bet on Booming Biotech is taking dead aim at this key market space…

Since 2011, they’ve been steadily developing assets to help them dominate it.

In fact, they’ve already got deals in place to develop and commercialize biosimilar versions of four key biopharmaceuticals currently in widespread use

These products alone could soon add billions to this company’s already booming bottom line. And there are many more to come, to be sure.

But as I’ve been saying, you cannot wait even a minute to buy into this one.

Since I first recommended it six weeks ago to readers of my flagship Eagle Financial research service, The Alpha Investor Letter

It’s up more than 12.5%.

So clearly, savvy investors are starting to sit up and take notice of this one…

If you move NOW, though, you can still get set up for the insane profits I’m betting this company will book for investors over the coming months.

Their ultra-low-risk, two-pronged business model is simply too good to fail — even in the risky biotech world.

In just a moment, I’ll show you how to get My Safest Bet on Booming Biotech, with all the details on this play…

Completely FREE OF RISK OR OBLIGATION on your part.

First, though, let me show you another one of my Miracle Island blockbusters…

ONE URGENT PLAY, 10 RED-HOT IRISH BIOPHARMAS

How would you like to put your money into ONE exceptionally low-risk investment…

And when I say “low risk”, I don’t just mean for a biotech, I mean low risk overall…

That’ll give you exposure to no less than TEN cutting-edge Irish biopharmas?

Well, that’s exactly what this one play does for you — and all from the safety and comfort of an established U.S. exchange.

Now, be advised: I recommended this play to readers of The Alpha Investor Letter at the same time as the biosimilar-focused company I just told you about…

And already, it’s up over 8%.

In other words, with such broad exposure within the sector…

This pick is starting to reflect the “smart money” opinion about Ireland’s rapid rise to the upper echelons of global biotechnology.

But I assure you, this fast 8% bump is just a warm-up

If you move with a purpose, there’s a TON of upside potential for you in this one.

One thing, though: even though this pick is traded on a reputable American exchange — and it’s easy as pie to buy into…

It is slightly different than simply scooping up shares of a stand-alone company on the New York Stock Exchange.

Don’t worry, though. To help you get into this incredible play as fast as possible…

I’m going to walk you through everything you need to know in my new Special Investment Report on this recommendation.

It’s called 10 Top-Tier Irish Biopharmas in One Low-Risk Investment.

And in just another moment, I’m going to show you how to get this report on its way to you immediately

It’s also 100% FREE OF RISK OR OBLIGATION.

Right now, though, let me just keep rolling with the “Miracle Island” moneymakers.

My third one of these is right here…

WATCH, WAIT, AND WIN ON THIS WORLD-BEATER BIOTECH

OK, there’s a little bit of a twist to this one. It’s a straight-up biotech stock with massive Miracle Island roots…

But it’s one I’m waiting for precisely the right moment to recommend to my readers.

Don’t get me wrong — this firm would be a no-brainer of a buy right this minute. In fact, it’s trading at a one-year forward P/E ratio of only 9.86 right now…

That’s 45% LOWER than the average stock in the S&P 500!

However, I don’t just slam out a recommendation in The Alpha Investor Letter just because something’s a great buy…

I want my readers to reap the lucrative benefits of the absolute best entry point on any play I offer them.

That’s why this particular stock has been on my “watch list” for several months now, as I wait for the right time to pull the trigger.

As I’ll show you in my third all-new biotech-focused Special Investment Report, Be Ready to Pounce on this World-Beating Biotech

This firm’s got an impressive stable of products across multiple high-demand areas.

These include cancer, cardiovascular health, immunodeficiency, inflammation, and much more.

More importantly…

They’ve also got one of the best track records in the biopharma universe at bringing these products to market profitably.

Now again — there’s no doubt in my mind that the moment is coming when I’ll recommend this stock to readers of The Alpha Investor Letter

And very likely, that moment will be soon.

You see, very recently, there’s been a major development with this stock…

In January of this year, they quietly acquired a company with a very promising new treatment for a chronic, deadly liver disease.

A disease that affects up to 20% of the people in the developed world!

It’s a deal worth as much as $470 million to the acquired company…

And God knows how much to the biopharma player I’m watching.

As usual, everything you need to know about this stock is in Be Ready to Pounce on this World-Beating Biotech

Which — like the others — I’m going to show you how to get 100% RISK-FREE.

And if you’re a reader of The Alpha Investor Letter (it’s easy to become one)…

You’ll know exactly WHEN to pounce on it, too.

OK, so there you have them: my three lowest-risk, highest potential return “Miracle Island” picks…

And again, they can all be yours — totally free of risk, obligation, or hassle…

Just say the one word I need to hear, and these plays will be on their way to you immediately

What’s that word?

It’s “yes”.

All you need to do to get my three new biotech-focused Special Investment Reports…

With ALL the details on my three most urgent and potentially lucrative plays on the Irish biopharma boom…

Is accept a no-risk subscription to my flagship investment research service, The Alpha Investor Letter.

That’s right — you’ll get these three potential “overnight millionaire” biotech picks absolutely FREE…

Simply for trying my money-back-guaranteed service on for size!

Even if you cancel your subscription for a full refund…

You KEEP these reports forever — plus all the money you make from the red-hot biotech picks you’ll find in them.

Remember, you risk NOTHING by trying The Alpha Investor Letter.

That’s because it’s covered by Eagle Financial Publications’ best-in-the-business money-back double guarantee.

Here’s that two-part guarantee, right now — in plain black and white:


report Guarantee #1:

If, at any time during the first 90 days of your subscription, you’re unhappy with The Alpha Investor Letter — for any reason — just let us know and you’ll receive a prompt refund of every penny you’ve paid. All materials you’ve received are yours to keep, FREE.
report Guarantee #2:

If you decide to cancel after the first 90 days, let us know and we’ll refund you the full value of the unused balance of your subscription to The Alpha Investor Letter. Again, all bonuses, issues, and Special Reports you’ve received or downloaded are yours to keep, FREE.

See?

You’re protected no matter what you decide to do.

So there’s no reason whatsoever not to accept a risk-free trial subscription to The Alpha Investor Letter

And get some money into play RIGHT NOW on my super-urgent Irish biotech picks.

Remember, I’m not promising that they’ll make you an “overnight millionaire”.

But I can promise you that millionaires are made every day in the biotech sphere.

And that the three biotech plays I’m offering to GIVE you today are the very best ones I know of with the chance to actually put you in that ballpark

Without the undue risks normally associated with biotech investing.

Now here’s the best part: trying The Alpha Investor Letter is super-easy…

Just click on the link below at any time.

Once you do that, simply choose which money-back-guaranteed subscription plan you want — one-year or two year…

And complete the simple sign-up instructions.

Whichever option you choose (they’re both incredible deals)…

These three super-urgent “Miracle Island” Special Investment Reports will be rushed to you ASAP.

But hold on a second — there’s a way to make this deal even sweeter.

Remember, my goal with The Alpha Investor Letter is to put mainstream American investors like you in front the very best moneymaking opportunities

No matter where on Earth they originate.

That’s why, in addition to my three new Irish biotech profit-plays…

I want you to give you seven more of my best investment recommendations — also completely free of charge.

They’re in a special bonus series of reports I’ve put together for those who choose the two-year subscription option on The Alpha Investor Letter.

Keep in mind that this two-year deal is the best value anyway (I’ll show you the shockingly low price shortly)…

And it’s ALSO covered by Eagle Publishing’s industry-leading double guarantee.

Again, just to be crystal clear about the terms of this guarantee, you could sign up for the two-year plan…

Get ALL 10 of my hottest and most urgent investment picks — including my three best Miracle Island plays…

And cancel within 90 days for a full refund of all your money.

Now, I’m not suggesting that you do this — I want you to join me for the long haul…

Because I know I can make you even richer that way!

I’m just saying that if you had a mind to take obscene advantage of this offer on The Alpha Investor Letter

The two-year subscription option is the way to go.

To prove that, let show you what you’ll get in this special BONUS series of reports the two-year plan includes:

BONUS Report #1) The ‘Buffett Clone’ that Beats Berkshire by 70%

In this Special Investment Report, you’ll find one of my favorite American companies…

It’s a small, overlooked specialty insurer that’s more profitable than Warren Buffett’s own heavily insurance-weighted Berkshire Hathaway.

In fact, it has beaten Berkshire handily since the late 1990s…

By playing Buffett’s own game better than he does!

And in this report, you’ll learn all the reasons why it’s going to KEEP beating Buffett’s baby for years to come…

Including the one “unfair advantage” that puts this firm head and shoulders above Berkshire — and everyone else in its segment.
BONUS Report #2) My #1 Way to Play India’s Stock Market Rally

As you may know, India’s stock market just hit its all-time high in January…

And by all the numbers and intelligence at my disposal, the rally’s going to keep going for months to come, if not years.

One major catalyst for this was the May 26th, 2014 election of Prime Minister Narendra Modi.

Dedicated to a strong economic development instead of government handouts, he’s been hailed as the “Ronald Reagan of India”.

Investors are taking notice, too — and plowing money into the Indian stock market, which has soared 41% in just the last year…

But in this report, I’ll show you what I consider the most profitable single play you can make on India’s market boom.
BONUS Report #3) Five Alpha Plays: Where the Smart Money’s Going Now

In this jam-packed Special Investment Report, you’ll get a “lightning round” of no less than FIVE moneymaking situations…

Four of which are emerging right here in the United States.

You’ll find ways to play energy (yes, it can be profitable even now), computing, rail transportation, the roaring U.S. dollar…

Even a great way to “shotgun” a major international market rally.

And as usual, you can cash in on ALL these opportunities with the safe domestic investment vehicles you’re already used to.

Ok, now let’s count them all up…

All in all — including my three red-hot Irish biotech plays…

That’s up to 10 FREE urgent investment recommendations you can get with your no-risk subscription to The Alpha Investor Letter.

So what are you waiting for?

Click on the button below — choose whichever subscription plan you want (again, they’re both ridiculously reasonable)…

Then start keeping an eye out for your FREE Special Investment Reports…

Plus everything else that comes with your money-back guaranteed subscription to The Alpha Investor Letter.

Here’s the full list of subscriber benefits you’ll get:

1 12 issues of The Alpha Investor Letter — Delivered to your e-mail inbox, this is where you’ll get my Stock of the Month: an urgent profit play that’s easy to make from American exchanges, along with in-depth analysis of why NOW is the time to buy…
1 The Alpha Investor Letter Weekly Hotline — Delivered straight from my desk to your e-Mail inbox every Wednesday, so you’re always abreast of the newest developments in each of my recommendations (plus what’s on my radar for the near future).
1 Global Spotlight — Here’s where you’ll get my brief synopsis of what’s happening in the world, with special concentration on how these events and conditions affect markets and smart-money investment trends.
1 24/7 Access to the Alpha Investor Web site — Once you sign up, you’ll get round-the-clock password-protected access to the entire gamut of service resources: stock research and portfolios, archives of all my past and current issues, updates, reports, and more.
1 Portfolio Updates — These include a performance analysis of my service’s current portfolio holdings, plus my proprietary ranking system that shows you how safe or risky each pick is at that particular moment, at a glance.
1 Monthly Checklist — This monthly checklist recaps all the actions I’ve recommended that you take as part of your subscription, including specific buying and selling advice.

I’m sure you’ll agree…

That’s a whole lot to get just for agreeing to accept a RISK-FREE subscription to The Alpha Investor Letter.

And remember — this is ON TOP of the Special Investment Reports you’ll get…

Which include up to 10 urgent and potentially hugely lucrative money-making plays.

Now here’s the best part of all: the price

For a limited time only, I can give you all these incredible benefits for up to 82% OFF

Normally, the everyday subscriber price of The Alpha Investor Letter is a very reasonable $249 a year.

But because these “Miracle Island” biotech plays are so time-sensitive

Remember, they’re already on the move, big-time…

I don’t want you to have even a moment’s hesitation about signing up, getting these picks — and getting some money into play ASAP.

That’s why I’ve asked Eagle Financial Publishing to let me offer an unprecedented deal to new subscribers of The Alpha Investor Letter

I’m happy to say, they agreed.

And so, I’m delighted to be able to offer you a full year’s worth of The Alpha Investor Letter for just $49.

That’s an unbelievable 80% OFF.

And remember, this includes my three new Special Investment Reports on the Irish biotech boom…

They’re yours to keep — even if you cancel for a full or partial refund.

This one-year deal is a great option if you just want the lowdown on my red-hot “Miracle Island” plays.

But again, if you want the greatest possible value out of your subscription to The Alpha Investor Letter

Then the unbelievably sharp two-year deal Eagle’s allowing me to offer you today is definitely the hot ticket.

Normally, 24 months’ worth of The Alpha Investor Letter costs $498…

But today, you can get two full years of this cutting-edge service for just $89.

That’s an unreal savings of more than 82% off!

And remember…

This incredible two-year subscription plan comes with SIX of my Special Investment Reports…

And a total of 10 red-hot picks (including my best biotech bets).

Bottom line: the choice is yours — there are no bad deals here.

Just click on the button below and select the option you want. Simple!

And either way, you’re protected by Eagle’s money-back double guarantee of satisfaction.

Once again, that’s all your money back within the first 90 days — for any reason…

Or a pro-rated refund of the remaining portion of your subscription at any point after 90 days.

All you need to do is let us know, and your money will be back in your pocket promptly — no questions asked.

There’s one small catch, though…

This incredible offer is SO cheap that my publisher is only making it available for a very limited time.

So if you want in on the “Miracle Island” plays that really could potentially make you an overnight millionaire (I’ve seen it happen)…

With the least possible risk — and the lowest possible expense

I urge you to click on the button below and sign up for The Alpha Investor Letter.

Seriously, even if you’re only doing it for the moneymaking recommendations you’ll find in your FREE Special Investment Reports…

I still want you to do it right now.

Because I know that not only will you be ecstatic with the money you make…

You’ll also be delighted with The Alpha Investor Letter itself.

I know this because I get letters and e-mails all the time from hard-working American investors just like you…

Investors who are thrilled with the results they’ve gotten from my service.

And now I want YOU to be one of them.

All you need to do is click below — and start cashing in.

Yours Truly,

Nicholas Vardy, CFA

P.S. I just received ANOTHER lucrative benefit I can offer you as part of this deal, no matter which subscription option you choose — one-year or two-year…

It’s Eagle Financial’s brand-new Master Report, The Top 12 Stocks for 2015.

It literally just hit my inbox as I was finishing up this bulletin — and it’s got three hot plays for this coming year from each of Eagle’s four editors: Dr. Mark Skousen, Doug Fabian, Chris Versace, and yours truly…

Just click below, and I’ll throw it into the deal as an extra perk for you! But hurry…

Only the first 200 people who respond to this offer will get this report.